肿瘤相关成纤维细胞在乳腺癌中的作用

doi:10.3760/cma.j.cn371439-20201208-00120

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (10): 614-617.doi: 10.3760/cma.j.cn371439-20201208-00120

肿瘤相关成纤维细胞在乳腺癌中的作用

王爱玲¹, 牛喜梅¹, 黄国福¹(), 冷晓玲²()

¹新疆医科大学第五附属医院肿瘤科,乌鲁木齐 830000
²新疆医科大学附属肿瘤医院超声科,乌鲁木齐 830011

收稿日期:2020-12-08 修回日期:2021-03-04 出版日期:2021-10-08 发布日期:2021-11-24
通讯作者: 黄国福,冷晓玲 E-mail:2508416490@qq.com;58281413@qq.com
基金资助:
国家自然科学基金(81660496)

Role of cancer-associated fibroblasts in breast cancer

Wang Ailing¹, Niu Ximei¹, Huang Guofu¹(), Leng Xiaoling²()

¹Department of Oncology, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
²Department of Ultrasound, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, China

Received:2020-12-08 Revised:2021-03-04 Online:2021-10-08 Published:2021-11-24
Contact: Huang Guofu,Leng Xiaoling E-mail:2508416490@qq.com;58281413@qq.com
Supported by:
National Natural Science Foundation of China(81660496)

摘要/Abstract

摘要：

乳腺癌细胞与肿瘤微环境之间的相互作用在乳腺癌发生发展过程中发挥至关重要的作用。肿瘤相关成纤维细胞是肿瘤微环境中含量丰富的异质性基质细胞,通过分泌多种细胞因子、生长因子和趋化因子参与肿瘤血管的生成、治疗抵抗和远处转移,将其作为乳腺癌的靶向治疗及临床预后的生物标志物具有巨大潜力,也可为乳腺癌辅助治疗提供新思路。

关键词: 乳腺肿瘤, 癌相关成纤维细胞, 肿瘤微环境

Abstract:

The interaction between breast cancer cells and the tumor microenvironment plays a vital role in the occurrence and development of breast cancer. Cancer-associated fibroblasts are heterogeneous stromal cells that are abundant in the tumor microenvironment. They participate in tumor angiogenesis, treatment resistance and distant metastasis by secreting a variety of cytokines, growth factors and chemokines. It has great potential as a biomarker for targeted therapy and clinical prognosis of breast cancer, and it can also provide new ideas for adjuvant treatment of breast cancer.

Key words: Breast neoplasms, Cancer-associated fibroblasts, Tumor microenvironment

王爱玲, 牛喜梅, 黄国福, 冷晓玲. 肿瘤相关成纤维细胞在乳腺癌中的作用[J]. 国际肿瘤学杂志, 2021, 48(10): 614-617.

Wang Ailing, Niu Ximei, Huang Guofu, Leng Xiaoling. Role of cancer-associated fibroblasts in breast cancer[J]. Journal of International Oncology, 2021, 48(10): 614-617.

参考文献 30

[1]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008. doi: 10.3760/cma.j.issn.0253-3766.2019.01.008
[2]	Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018[J]. Eur J Cancer, 2018, 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. doi: S0959-8049(18)30955-9 pmid: 30100160
[3]	Shimura T, Sasatani M, Kawai H, et al. Radiation-induced myofibroblasts promote tumor growth via mitochondrial ROS-activated TGFβ signaling[J]. Mol Cancer Res, 2018, 16(11):1676-1686. DOI: 10.1158/1541-7786.MCR-18-0321. doi: 10.1158/1541-7786.MCR-18-0321
[4]	Nurmik M, Ullmann P, Rodriguez F, et al. In search of definitions: cancer-associated fibroblasts and their markers[J]. Int J Cancer, 2020, 146(4):895-905. DOI: 10.1002/ijc.32193. doi: 10.1002/ijc.32193
[5]	Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment[J]. Front Immunol, 2019, 10:1835. DOI: 10.3389/fimmu.2019.01835. doi: 10.3389/fimmu.2019.01835 pmid: 31428105
[6]	Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing[J]. Nat Commun, 2018, 9(1):5150. DOI: 10.1038/s41467-018-07582-3. doi: 10.1038/s41467-018-07582-3 pmid: 30514914
[7]	Li A, Chen P, Leng Y, et al. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway[J]. Oncogene, 2018, 37(45):5952-5966. DOI: 10.1038/s41388-018-0379-9. doi: 10.1038/s41388-018-0379-9
[8]	Gok Yavuz B, Gunaydin G, Gedik ME, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1⁺ TAMs[J]. Sci Rep, 2019, 9(1):3172. DOI: 10.1038/s41598-019-39553-z. doi: 10.1038/s41598-019-39553-z
[9]	Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer[J]. Cancer Discov, 2020, 10(9):1330-1351. DOI: 10.1158/2159-8290.CD-19-1384. doi: 10.1158/2159-8290.CD-19-1384 pmid: 32434947
[10]	Cremasco V, Astarita JL, Grauel AL, et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors[J]. Cancer Immunol Res, 2018, 6(12):1472-1485. DOI: 10.1158/2326-6066.CIR-18-0098. doi: 10.1158/2326-6066.CIR-18-0098 pmid: 30266714
[11]	Chen IX, Chauhan VP, Posada J, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer[J]. Proc Natl Acad Sci U S A, 2019, 116(10):4558-4566. DOI: 10.1073/pnas.1815515116. doi: 10.1073/pnas.1815515116 pmid: 30700545
[12]	Morgan MM, Livingston MK, Warrick JW, et al. Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model[J]. Sci Rep, 2018, 8(1):7139. DOI: 10.1038/s41598-018-25461-1. doi: 10.1038/s41598-018-25461-1 pmid: 29740030
[13]	Feng F, Zhu X, Wang C, et al. Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells[J]. Cancer Cell Int, 2018, 18:127. DOI: 10.1186/s12935-018-0616-x. doi: 10.1186/s12935-018-0616-x pmid: 30202238
[14]	Suh J, Kim DH, Lee YH, et al. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling[J]. Mol Carcinog, 2020, 59(9):1028-1040. DOI: 10.1002/mc.23233. doi: 10.1002/mc.23233
[15]	Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun, 2019, 10(1):4375. DOI: 10.1038/s41467-019-12370-8. doi: 10.1038/s41467-019-12370-8 pmid: 31558756
[16]	Lappano R, Talia M, Cirillo F, et al. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs)[J]. J Exp Clin Cancer Res, 2020, 39(1):153. DOI: 10.1186/s13046-020-01667-y. doi: 10.1186/s13046-020-01667-y
[17]	Ren J, Smid M, Iaria J, et al. Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression[J]. Breast Cancer Res, 2019, 21(1):109. DOI: 10.1186/s13058-019-1194-0. doi: 10.1186/s13058-019-1194-0
[18]	Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling[J]. Cancer Lett, 2019, 442:320-332. DOI: 10.1016/j.canlet.2018.10.015. doi: 10.1016/j.canlet.2018.10.015
[19]	Kugeratski FG, Atkinson SJ, Neilson LJ, et al. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling[J]. Sci Signal, 2019, 12(567): eaan8247. DOI: 10.1126/scisignal.aan8247. doi: 10.1126/scisignal.aan8247
[20]	De Francesco EM, Sims AH, Maggiolini M, et al. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment[J]. Breast Cancer Res, 2017, 19(1):129. DOI: 10.1186/s13058-017-0923-5. doi: 10.1186/s13058-017-0923-5
[21]	Limoge M, Safina A, Beattie A, et al. Tumor-fibroblast interactions stimulate tumor vascularization by enhancing cytokine-driven production of MMP9 by tumor cells[J]. Oncotarget, 2017, 8(22):35592-35608. DOI: 10.18632/oncotarget.16022. doi: 10.18632/oncotarget.16022
[22]	Eiro N, González L, Martínez-Ordoñez A, et al. Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis[J]. Cell Oncol (Dordr), 2018, 41(4):369-378. DOI: 10.1007/s13402-018-0371-y. doi: 10.1007/s13402-018-0371-y
[23]	Hu YB, Yan C, Mu L, et al. Correction: Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance[J]. Oncogene, 2019, 38(35):6319-6321. DOI: 10.1038/s41388-019-0863-x. doi: 10.1038/s41388-019-0863-x pmid: 31366984
[24]	Fernández-Nogueira P, Mancino M, Fuster G, et al. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation[J]. Clin Cancer Res, 2020, 26(6):1432-1448. DOI: 10.1158/1078-0432.CCR-19-0353. doi: 10.1158/1078-0432.CCR-19-0353 pmid: 31699826
[25]	Cui Q, Wang B, Li K, et al. Upregulating MMP-1 in carcinoma-associated fibroblasts reduces the efficacy of Taxotere on breast cancer synergized by collagen Ⅳ[J]. Oncol Lett, 2018, 16(3):3537-3544. DOI: 10.3892/ol.2018.9092. doi: 10.3892/ol.2018.9092
[26]	Suh J, Kim DH, Surh YJ. Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk[J]. Arch Biochem Biophys, 2018, 643:62-71. DOI: 10.1016/j.abb.2018.02.011. doi: 10.1016/j.abb.2018.02.011
[27]	Barone I, Vircillo V, Giordano C, et al. Activation of farnesoid X receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts[J]. Cancer Lett, 2018, 437:89-99. DOI: 10.1016/j.canlet.2018.08.026. doi: S0304-3835(18)30544-5 pmid: 30176263
[28]	Geng F, Guo J, Guo QQ, et al. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer[J]. Vaccine, 2019, 37(31):4382-4391. DOI: 10.1016/j.vaccine.2019.06.012. doi: S0264-410X(19)30773-X pmid: 31202521
[29]	Fang J, Xiao L, Joo KI, et al. A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice[J]. Int J Cancer, 2016, 138(4):1013-1023. DOI: 10.1002/ijc.29831. doi: 10.1002/ijc.29831
[30]	Eiro N, Cid S, Fernández B, et al. MMP11 expression in intratumoral inflammatory cells in breast cancer[J]. Histopathology, 2019, 75(6):916-930. DOI: 10.1111/his.13956. doi: 10.1111/his.13956

肿瘤相关成纤维细胞在乳腺癌中的作用

Role of cancer-associated fibroblasts in breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	傅旖, 马辰莺, 张露, 周菊英. 生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	刘筱迪, 苏剑飞, 张静娴, 卫雪芹, 贾英杰. 髓源性抑制细胞在肿瘤血管生成中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 50-54.
[7]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[14]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.